Australia · Delayed Price · Currency is AUD Saluda Medical Statistics
Total Valuation
Saluda Medical has a market cap or net worth of AUD 114.67 million. The enterprise value is 87.40 million.
| Market Cap | 114.67M |
| Enterprise Value | 87.40M |
Important Dates
The next estimated earnings date is Wednesday, November 25, 2026.
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Saluda Medical has 252.02 million shares outstanding. The number of shares has increased by 4,886.98% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 252.02M |
| Shares Change (YoY) | +4,886.98% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 25.79% |
| Float | 5.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.88 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.43, with a Debt / Equity ratio of 1.83.
| Current Ratio | 5.43 |
| Quick Ratio | 4.21 |
| Debt / Equity | 1.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.85 |
| Interest Coverage | -15.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -56.96% |
| Return on Invested Capital (ROIC) | -71.13% |
| Return on Capital Employed (ROCE) | -93.00% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 980,060 |
| Profits Per Employee | -2.60M |
| Employee Count | 133 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Saluda Medical has paid 1.02 million in taxes.
| Income Tax | 1.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 37.75 |
| Average Volume (20 Days) | 531,669 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Saluda Medical had revenue of AUD 130.35 million and -346.36 million in losses. Loss per share was -2.14.
| Revenue | 130.35M |
| Gross Profit | 63.72M |
| Operating Income | -208.83M |
| Pretax Income | -215.19M |
| Net Income | -346.36M |
| EBITDA | -206.22M |
| EBIT | -208.83M |
| Loss Per Share | -2.14 |
Balance Sheet
The company has 171.46 million in cash and 144.19 million in debt, with a net cash position of 27.27 million or 0.11 per share.
| Cash & Cash Equivalents | 171.46M |
| Total Debt | 144.19M |
| Net Cash | 27.27M |
| Net Cash Per Share | 0.11 |
| Equity (Book Value) | 78.86M |
| Book Value Per Share | 0.31 |
| Working Capital | 211.48M |
Cash Flow
In the last 12 months, operating cash flow was -167.65 million and capital expenditures -1.07 million, giving a free cash flow of -168.72 million.
| Operating Cash Flow | -167.65M |
| Capital Expenditures | -1.07M |
| Depreciation & Amortization | 2.53M |
| Net Borrowing | 34.37M |
| Free Cash Flow | -168.72M |
| FCF Per Share | -0.67 |
Margins
Gross margin is 48.89%, with operating and profit margins of -160.21% and -165.87%.
| Gross Margin | 48.89% |
| Operating Margin | -160.21% |
| Pretax Margin | -165.09% |
| Profit Margin | -165.87% |
| EBITDA Margin | -158.21% |
| EBIT Margin | -160.21% |
| FCF Margin | n/a |
Dividends & Yields
Saluda Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4,886.98% |
| Shareholder Yield | -4,886.98% |
| Earnings Yield | -302.05% |
| FCF Yield | -147.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Saluda Medical is 2.13, which is 401.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2.13 |
| Price Target Difference | 401.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 43.00% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Saluda Medical has an Altman Z-Score of -5.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.82 |
| Piotroski F-Score | 4 |